Today: 9 January 2026
Subscribe
Browse Category

Biotech Stocks News 20 December 2025 - 24 December 2025

Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (Nasdaq: RGC) is once again reminding markets that “biotech stock” plus “low float” can equal “physics optional.” By the close of trading on December 24, RGC finished at $24.60, down 2.57% from
24 December 2025
····
Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

December 23, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is back in the spotlight on Tuesday after another sharp move higher, extending a volatile December run that’s pulled in momentum traders—and raised fresh questions about fundamentals, governance, and legal
23 December 2025
····
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. (NASDAQ: GILD) opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025,
22 December 2025
····
Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Dec. 22, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” into a deal-driven stock, after BioMarin Pharmaceutical announced an all-cash agreement to acquire Amicus for $14.50 per share. With shares trading around $14.18
22 December 2025
····
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely
22 December 2025
····
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash
21 December 2025
····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50
20 December 2025
····
1 2 3 4 5
Go toTop